Dr. Lusk is part of team that has published “Calcitonin Gene–Related Peptide Inhibitors and Cardiovascular Events in Patients With Migraine” in Neurology. This retrospective cohort study used insurance claims data to evaluate whether initiating calcitonin gene–related peptide (CGRP) inhibitors for migraine is associated with cardiovascular risk. Among individual outcomes, only ischemic stroke showed a significant increase, while myocardial infarction, revascularization, retinal artery occlusion, and intracranial hemorrhage were not significantly associated. Overall, initiation of CGRP inhibitors was linked to a modest increase in cardiovascular risk in patients with migraine.

View Publication: https://doi.org/10.1212/WNL.0000000000214479